

Fig. S1 Characterization of the morphology of hMSC-DP under SF culture conditions. **a-b** Cell morphology analysis by high-content imaging. The nuclear area (a) and cell area (b) of DPSCs and SHED are shown in SE and SF culture conditions. n = 3 for each group. **c** Cellular senescence assay. The percentage of SA-β-gal positive cells was calculated and compared between SE and SF culture conditions. $n = 3 \sim 5$ for each group. SE, serum; SF, serum-free. Data shown as mean ± SEM. ns, not significant.



Fig. S2 Proliferation capacity of hMSC-DP under SF culture conditions. **a** CFU-F assay. The numbers of colonies of hMSC-DP under SE or SF culture conditions were calculated and compared. n = 3 for each group. **b** Population doubling scores were calculated and compared between SE and SF culture conditions in DPSC and SHED groups, independently. n = 3 for each group. **c** EdU assay. The percentage of EdU-positive cells were calculated and compared between SE and SF culture conditions in DPSC and SF culture

independently. n = 3 for each group. Scale bar = 200 μ m. SE, serum; SF, serum-

free. Data shown as mean \pm SEM. *p < 0.05. ns, not significant.



Fig. S3 Surface phenotypic profiles and in vitro immunoregulation ability of hMSC-DP. a-b Flow cytometry showed the percentage of CD146-positive hMSC-DP under SE or SF culture conditions at P5, P10 and P20 (a). The percentage of CD146-positive cells was compared between SE and SF culture conditions (b). n = 3 for each group. c The percentage of apoptotic T cells was calculated in SE and SF culture conditions. n = 3 for each group. SE, serum; SF, serum-free. Data shown as mean \pm SEM. *p < 0.05. ns, not significant.





Fig. S4 Multilineage differentiation of hMSC-DP. **a** Alizarin red staining assay. The osteogenic capacity was compared between SE and SF culture conditions at P5, P10 and P20. n = 3 for each group. **b** Oil red O staining assay. The adipogenic capacity of hMSC-DP was compared between SE and SF culture conditions at P5, P10 and P20. n = 3 for each group. Scale bar = 50 μ m. SE, serum; SF, serum-free. Data shown as mean \pm SEM. ***p* < 0.01. ns, not significant.



Fig. S5 Therapeutic effects of hMSC-DP on experimental colitis. a Disease activity index (DAI) of DPSC- and SHED-treated groups was compared between SE and SF culture conditions at P5, P10 and P20. n = 3 for each group.
b The colon length after DPSC and SHED treatment was compared between SE and SF culture conditions at P5, P10 and P20. n = 3 for each group.

Histological structure was examined by H&E staining. The histological score of each group was compared between SE and SF culture conditions. n = 3 for each group. Scale bar = 100 µm. SE, serum; SF, serum-free. T Data shown as mean \pm SEM. ns, not significant.



R²=0.9365

40 60

40 60

R²=0. 7787

20

20



Fig. S6 The expression level of CD146 is associated with hMSC-DP properties. **a** The correlation of CD146 with experimental parameters. **b** Linear regression plots showed the correlation between CD146 expression and experimental parameters including CFU-F clones, percentage of EdU positive cells, percentage of Alizarin red positive area, percentage of SA-β-gal positive cells, DAI scores, HAI scores and colon length.